| With $80M, ReCode Looks to Advance RNA Therapies for Lung Diseases | Sarah de Crescenzo | 03/26/20 | San Francisco |
| SpringWorks, Armed with Ex-Pfizer Cancer Drugs, Reloads with $125M | Ben Fidler | 04/01/19 | New York |
| Turning Point Therapeutics Plans IPO to Advance Targeted Cancer Drugs | Sarah de Crescenzo | 03/22/19 | San Diego |
| Passage Bio Gets $116M As Wilson, Yamada Team Up On Gene Therapy Again | Ben Fidler | 02/14/19 | National |
| Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More | Frank Vinluan | 10/26/18 | National |
| TP Therapeutics Names New CEO, Gets $80M More for Cancer Drug Push | Sarah de Crescenzo | 10/19/18 | San Diego |
| Bio Roundup: IDO Fallout, Express Scripts Dumps Amgen, Isaly Out & More | Ben Fidler | 05/04/18 | National |
| OrbiMed Founder Isaly Steps Down After Sexual Harassment Report | Corie Lok | 12/08/17 | New York |
| Report: Sexual Harassment Claims Hit OrbiMed Founder Sam Isaly | David Holley | 12/06/17 | New York |
| SpringWorks Spins Out of Pfizer With $103M to Give Shelved Drugs New Life | Ben Fidler | 09/25/17 | New York |
| Bio Roundup: $1B Deals, Data Bumps, Acorda’s Lumps, Generic OKs & More | Alex Lash | 08/11/17 | National |
| For Parkinson’s, Two New Drugs Coming As Prevail Gets Started in NY | Ben Fidler | 08/09/17 | New York |
| Not Resting on Hemophilia Biz, Bioverativ Pays $400M For True North | Ben Fidler | 05/23/17 | Boston |
| Gates Foundation Leads $45.5M Round for Gerngross’s Biotech Arsanis | David Holley | 04/26/17 | Boston |
| Ex-Dendreon CEO, Gold, Returns to Wall Street as Alpine, Nivalis Merge | Ben Fidler | 04/18/17 | Seattle |
| Aiming At P53, Cancer’s Hard Target, PMV Pharma Raises $74M | Ben Fidler | 02/22/17 | New York |
| Cleave Bio Gets $37M From Celgene, Others For Clinical Push | David Holley | 08/08/16 | San Francisco |
| Audentes Prices $75M IPO As Gene Therapy Eyes First U.S. Approval | Ben Fidler | 07/20/16 | San Francisco |
| Retooled Selecta Bio Takes Crossover Cash to IPO Queue | Ben Fidler | 05/24/16 | Boston |
| West Coast Biotech Roundup: Gilead, Adicet, Otonomy, Fate & More | Bruce V. Bigelow | 01/29/16 | San Diego |
| Adicet Joins the Immunotherapy Fray With $51M and Mystery Cells | Alex Lash | 01/27/16 | San Francisco |
| Exosome Diagnostics Closes $60M Series B for Liquid Biopsy Test | David Holley | 01/07/16 | Boston |
| With $100M, Guardant Health to Expand Reach of Blood Test for Cancer | David Holley | 01/07/16 | San Francisco |
| Bristol-Myers to Add Cardioxyl’s Heart Failure Drug With $300M Deal | Frank Vinluan | 11/02/15 | Raleigh Durham |
| Alector Raises $32M For Immune-Based Neuro Drug Development | Alex Lash | 09/16/15 | San Francisco |
| Avitide Gets $7.6M More to Purify Complex Biologics | Ben Fidler | 08/06/15 | Boston |
| Gene Therapy Upstart Dimension Nabs $65M From “Crossover” Backers | Ben Fidler | 04/21/15 | Boston |
| Pop That Bubble: 5 Reasons Biotech Needs A Different Metaphor | Alex Lash | 04/14/15 | National |
| West Coast Biotech Roundup: Juno, Tekmira, True North, aTyr & More | Alex Lash | 04/10/15 | Seattle |
| With $35M Infusion, True North Moves Rare Disease Drug Into Clinic | Alex Lash | 04/07/15 | San Francisco |
